Table 3

Successful adoptive immunotherapy of LCMV-ARM-carrier mice requires LCMV-ARM-primed B cells and CD4+ T cells as well as CD8+ T cells

Exp.Transferred lymphocytesVirus titer*
BloodBrainSpleenKidney
1d60 ARM immune cells<1.7<1.8<2.14.2 ± 0.2
d8 ARM immune cells3.7 ± 0.44.6 ± 0.45.2 ± 0.35.8 ± 0.4
2d60 ARM immune cells
 CD8+ T cell depleted4.6 ± 0.94.4 ± 0.55.7 ± 0.46.0 ± 0.5
 CD4+ T cell depleted3.4 ± 0.34.8 ± 0.25.6 ± 0.66.0 ± 0.2
 B cell depleted4.2 ± 0.36.2 ± 0.55.7 ± 0.46.4 ± 0.2
3WE-immune cells into ARM-carrier mice<1.7<1.7<2.13.3
ARM-immune cells into WE-carrier mice4.4 ± 0.44.4 ± 0.34.6 ± 0.66.2 ± 0.5
  • In experiment (Exp.) 1, C57BL/6 mice were infected i.v. with 200 pfu of LCMV-ARM. Spleen cells of these mice were taken either 8 days (d8 ARM-immune cells) or 60 days (d60 ARM-immune cells) after infection, and 108 cells were adoptively transferred into C57BL/6 mice persistently infected with LCMV-ARM. In experiment 2, specific lymphocyte subpopulations were depleted by magnetic cell sorting before transfer. In experiment 3, 108 d60 LCMV-ARM-immune or d60 LCMV-WE-immune spleen cells were adoptively transferred into C57BL/6 mice persistently infected with one of the two LCMV isolates. At 100 days after cell transfer, the carrier mice were killed and virus was quantified. 

  • * Virus titers are expressed as plaque-forming units per milliliter of blood or gram of organ (log10) on day 100 after cell transfer and are means ± SEM of three to five mice. Experiments were repeated twice with similar results.